<DOC>
	<DOCNO>NCT01870102</DOCNO>
	<brief_summary>Part 1 : A randomized , open Label , multiple dos , cross-over , phase I trial investigate pharmacokinetics Pelubiprofen IR ( Pelubiprofen 30mg ) TID Pelubiprofen SR ( Pelubiprofen 45 mg ) BID healthy male volunteer Part 2 : A randomized , open label , single dose , cross-over , Phase I trial investigate food effect Pelubiprofen SR ( Pelubiprofen 45 mg ) healthy male volunteer</brief_summary>
	<brief_title>Phase 1 Study Compare Pharmacokinetic Characteristics Food Effect Pelubiprofen ( 30mg ) Tablet IR Pelubiprofen SR ( Pelubiprofen 45 mg ) Tablet Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Adult healthy male age 20~40 year BMI value 19 kg/m2 , 27 kg/m2 Subjects whose blood pressure ; systolic BP 90mmHg 140mmHg , diastolic BP 60mmHg 90mmHg , stable station pulse 45 bpm 100 bpm Subjects agree double protective contraception able certificate already sterilization operation 1 day administration Investigational new drug within 14 day completion Subjects voluntarily agree write consent Subjects clinically significant disease past medical history hepatic , renal , GI tract , respiratory , musculoskeletal , endocrine , neuropsychiatry , blood tumor cardiovascular system Subjects GI tract disease ( eg . Crohn 's disease , peptic ulcer etc . ) surgery ( except appendectomy herniotomy ) influence administration Investigational new drug Subjects hypersensitivity reaction clinically significant disease drug ( Aspirin , NSAID antiinflammatory agent antibiotic ) include Pelubiprofen Food</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>